Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron M Goodman

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
The Lancet. Haematology|March 26, 2021
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic reviewGhulam Rehman Mohyuddin, Kelly Koehn, Douglas Sborov, et al.
JCO Precision Oncology|July 7, 2017
Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid MalignanciesAaron M Goodman, Michael Choi, Matthew Wieduwilt, et al.
Cancers|September 28, 2023
Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution ExperienceAaron Trando, Anna Ter-Zakarian, Phillip Yeung, et al.
EJNMMI Research|December 9, 2020
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[<sup>18</sup>F]FDG PET (positron emission tomography) scan in cancer patientsAmin Haghighat Jahromi, Donald A Barkauskas, Matthew Zabel, et al.
Journal of Cancer Policy|February 11, 2023
Quality of content reporting on two major oncology media websites: OncLive and Targeted OncologyNaman Sharma, Cole Wayant, Karun Neupane, et al.
Therapeutic Advances in Medical Oncology|September 2, 2024
Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignanciesAh-Reum Jeong, Aaron H Trando, Sean D Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based ImmunotherapyYulian Khagi, Aaron M Goodman, Gregory A Daniels, et al.
Oncoimmunology|February 6, 2018
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapiesAaron M Goodman, Shumei Kato, Philip R Cohen, et al.
Journal of Cutaneous Pathology|December 14, 2020
Cutaneous intralymphatic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma arising in a patient with multiple rounds of breast implantsHuan-You Wang, John A Thorson, Brian R Hinds, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic reviewWilliam Wesson, Vincent L Galate, Douglas W Sborov, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
The Lancet. Haematology|March 26, 2021
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic reviewGhulam Rehman Mohyuddin, Kelly Koehn, Douglas Sborov, et al.
JCO Precision Oncology|July 7, 2017
Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid MalignanciesAaron M Goodman, Michael Choi, Matthew Wieduwilt, et al.
Cancers|September 28, 2023
Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution ExperienceAaron Trando, Anna Ter-Zakarian, Phillip Yeung, et al.
EJNMMI Research|December 9, 2020
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[<sup>18</sup>F]FDG PET (positron emission tomography) scan in cancer patientsAmin Haghighat Jahromi, Donald A Barkauskas, Matthew Zabel, et al.
Journal of Cancer Policy|February 11, 2023
Quality of content reporting on two major oncology media websites: OncLive and Targeted OncologyNaman Sharma, Cole Wayant, Karun Neupane, et al.
Therapeutic Advances in Medical Oncology|September 2, 2024
Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignanciesAh-Reum Jeong, Aaron H Trando, Sean D Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based ImmunotherapyYulian Khagi, Aaron M Goodman, Gregory A Daniels, et al.
Oncoimmunology|February 6, 2018
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapiesAaron M Goodman, Shumei Kato, Philip R Cohen, et al.
Journal of Cutaneous Pathology|December 14, 2020
Cutaneous intralymphatic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma arising in a patient with multiple rounds of breast implantsHuan-You Wang, John A Thorson, Brian R Hinds, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic reviewWilliam Wesson, Vincent L Galate, Douglas W Sborov, et al.
Pageof 8